ARTICLE TITLE: Lung Cancer—Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual

CONTINUING MEDICAL EDUCATION ACCREDITATION AND DESIGNATION STATEMENT:
Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Blackwell Futura Media Services designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION ACCREDITATION AND DESIGNATION STATEMENT:
The American Cancer Society (ACS) is accredited as a provider of continuing nursing education (CNE) by the American Nurses Credentialing Center’s Commission on Accreditation.
Accredited status does not imply endorsement by the ACS or the American Nurses Credentialing Center of any commercial products displayed or discussed in conjunction with an educational activity. The ACS gratefully acknowledges the sponsorship provided by Wiley for hosting these CNE activities.

EDUCATIONAL OBJECTIVES:
After reading the article “Lung Cancer—Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual,” the learner should be able to:
1. Summarize significant modifications for staging of lung cancers in the recently released eighth edition of the American Joint Committee on Cancer (AJCC) Staging Manual.
2. Describe the clinical significance of modifications for staging of lung cancers in the recently released eighth edition of the AJCC Staging Manual.

ACTIVITY DISCLOSURES:
No commercial support has been accepted related to the development or publication of this activity.

ACS CONTINUING PROFESSIONAL EDUCATION COMMITTEE DISCLOSURES:
Editor: Ted Gansler, MD, MBA, MPH, has no financial relationships or interests to disclose.
Associate Editor: Durado Brooks, MD, MPH, has no financial relationships or interests to disclose.
Lead Nurse Planner: Cathy Meade, PhD, RN, FAAN, has no financial relationships or interests to disclose.
Editorial Advisory Member: Richard C. Wender, MD, has no financial relationships or interests to disclose.

NURSING ADVISORY BOARD DISCLOSURES:
Maureen Berg, RN, has no financial relationships or interests to disclose.
Susan Jackson, RN, MPH, has no financial relationships or interests to disclose.
Barbara Lesser, BSN, MSN, has no financial relationships or interests to disclose.

AUTHOR DISCLOSURES:
Hisao Asamura, MD, reports lecture fees from Johnson and Johnson Company and Medtronic. Valerie W. Rusch, MD, reports grants from Genelux, Inc., outside the submitted work. William D. Travis, MD, and Ramón Rami-Porta, MD, have no financial relationships or interests to disclose.
The peer reviewers disclose no conflicts of interest. Identities of the reviewers are not disclosed in line with the standard accepted practices of medical journal peer review.

SCORING
A score of 70% or better is needed to pass a quiz containing 10 questions (7 correct answers), or 80% or better for 5 questions (4 correct answers).

CME INSTRUCTIONS ON RECEIVING CME CREDIT
This activity is intended for physicians. For information concerning the applicability and acceptance of CME credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within 1.5 hours; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to 2 years from the time of initial publication.

CNE INSTRUCTIONS ON RECEIVING CNE CREDIT
This activity is intended for nurses. For information concerning the applicability and acceptance of CNE credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within 1.5 hours; nurses should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to 2 years from the time of initial publication.

FOLLOW THESE STEPS TO EARN CREDIT
• Log on to acsjournals.com/ce.
• Read the target audience, educational objectives, and activity disclosures.
• Read the activity contents in print or online format.
• Reflect on the activity contents.
• Access the examination, and choose the best answer to each question.
• Complete the required evaluation component of the activity.
• Claim your certificate.

This activity will be available for CME/CNE credit for 1 year following its launch date. At that time, it will be reviewed and potentially updated and extended for an additional 12 months.

All CME/CNE quizzes are offered online FREE OF CHARGE. Please log in at acsjournals.com/ce. New users can register for a FREE account. Registration will allow you to track your past and ongoing activities. After successfully completing each quiz, you may instantly print a certificate, and your online record of completed courses will be updated automatically.
Lung Cancer—Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual

Ramón Rami-Porta, MD1; Hisao Asamura, MD2; William D. Travis, MD3; Valerie W. Rusch, MD4

Abstract: The revision for the eighth edition of the tumor, node, and metastasis (TNM) classification of lung cancer was based on analyses of the International Association for the Study of Lung Cancer database, which included 77,156 evaluable patients diagnosed with lung cancer from 1999 to 2010. Among tumor (T) descriptors, the following new tumor-size groups were created: T1a, ≤1 cm; T1b, >1 to 2 cm; T1c, >2 to 3 cm; T2a, >3 to 4 cm; T2b, >4 to 5 cm; T3, >5 to 7 cm; and T4, >7 cm. Tis and T1mi were introduced for adenocarcinoma in situ and minimally invasive adenocarcinoma, respectively. Endobronchial tumors located <2 cm from the carina have better prognosis than those with any other T3 descriptor and were classified as T2. Total atelectasis/pneumonitis was classified as a T2 descriptor, because it has a T2 prognosis. Diaphragmatic invasion is now T4. Visceral pleural invasion remains unchanged, and mediastinal pleura invasion, which is seldom used, disappears as a T descriptor. The lymph node (N) component descriptors are unchanged, but the number of involved nodal stations has prognostic impact. For the metastasis (M) component, M1a (intrathoracic metastases) remains unchanged, but extrathoracic metastases are divided into a single extrathoracic metastasis (new M1b) and multiple extrathoracic metastases in a single organ or multiple organs (M1c). Stage IA is now divided into IA1, IA2, and IA3; stage IB is subdivided into IB1 and IB2; stage III is subdivided into IIIA, IIIB, and IIIC; and stage IV is subdivided into IVa, IVb, and IVc. This revision enhances our capacity for prognostication and will have an important impact in the management of patients with lung cancer and in future research. CA Cancer J Clin 2017;67:138–155. © 2017 American Cancer Society.

Keywords: lung cancer, lung cancer staging, nonsmall cell lung cancer, regional lymph node map, small cell lung cancer, stage grouping, TNM classification, visceral pleural invasion

Practical Implications for Continuing Education

> More subgroups are created based on tumor size.
> Quantification of nodal disease has prognostic impact.
> Different categories are created for single and multiple extrathoracic metastases.

Introduction

The revisions introduced in the eighth edition of the tumor, node, and metastasis (TNM) classification of lung cancer have emanated from analyses of the International Association for the Study of Lung Cancer (IASLC) database. This has meant the consolidation of a data-based process for the periodic revision of the classification, which started in the early 2000s with the revision of the sixth edition toward the seventh edition.1,2 The purpose of this article is to summarize the characteristics of the
The database used for the latest revision; to describe the most important findings from the multiple analyses performed leading to the recommendations for changes introduced in the eighth edition; to comment on those situations beyond the official T, N, and M descriptors that need rules for homogeneous classification; and to point out the clinical and research implications of the new classification. The eighth edition of the TNM classification will be enacted on January 1, 2017.

The Database

The IASLC database used to inform the eighth edition of the TNM classification of lung cancer included data on a total of 94,708 patients diagnosed with lung cancer from 1999 to 2010, originating from 35 different databases in 16 countries on 5 continents. The database was stored, managed, and analyzed by Cancer Research And Biostatistics, a biostatistical agency appointed by the IASLC. After exclusions, 77,156 patients remained evaluable, including 70,967 with nonsmall cell lung cancer and 6189 with small cell lung cancer. Nearly 85% of the patients underwent surgical treatment, either alone (57.7%) or with chemotherapy (21.1%), radiotherapy (1.5%), or both (4.4%). Most of these patients were from Europe and Asia, but there also were patients from North and South America and from Australia. Data on 73,251 patients had been retrospectively registered but contained the necessary information to study the T and the N descriptors. For the M descriptors, data on 3905 patients prospectively collected through the online electronic data capture (EDC) system provided detailed information on the number and location of metastatic sites to allow the recommendation of some changes in the M descriptors. The methods and validation used in the analyses of the database have been described in detail elsewhere.

The Innovations

Table 1 summarizes the innovations introduced for the T, N, and M descriptors in the eighth edition of the classification.

### The T Descriptors

The analysis of the T component is complex, because it has many descriptors: tumor size, endobronchial location, atelectasis/pneumonitis, and the invasion of the many anatomic structures around the lung. The prognosis of each
individual T descriptor was assessed in patients who had pathologically staged tumors with and without nodal involvement that were completely and incompletely resected. The same analyses were then performed in the population of patients who had clinically staged tumors, either with or without nodal involvement. All findings were consistent in all studied populations. These analyses showed that the 3-cm cutoff point still separates T1 from T2 tumors, but tumor size arises as a more important prognostic factor, because, from ≤1 cm to 5 cm, each centimeter separates tumors with a significantly different prognosis. Tumors measuring from >5 to ≤7 cm (now T3) were found to have a worse prognosis than was determined in the previous editions of the TNM classification, and those >7 cm (now T4) were associated with a prognosis similar to that of other descriptors in the T4 category. Another important finding was that, in the analyses of this series, endobronchial location <2 cm from the carina (a T3 descriptor in the seventh edition), but without involvement of the carina, had the same prognosis as endobronchial location >2 cm from the carina (a T2 descriptor in the seventh edition). The same occurred with total atelectasis/pneumonitis, ie, atelectasis or pneumonitis involving the whole lung (a T3 descriptor in the seventh edition): in the analyses of the new database, it had the same prognosis as partial atelectasis/pneumonitis, ie, atelectasis or pneumonitis involving part of the lung and extending to the hilar region (a T2 descriptor in the seventh edition). Conversely, invasion of the diaphragm (a T3 descriptor in the seventh edition, T4 in the eighth edition) had a worse prognosis than other T3 descriptors that was similar to the prognosis of T4 tumors. Finally, it was found that mediastinal pleural invasion was rarely used as a descriptor. In the light of these findings, the recommendations for the T descriptors in the eighth edition are shown in Table 1: New categories were introduced based on tumor size, endobronchial location <2 cm from carina and total atelectasis/pneumonitis were down staged (from T3 to T2), and invasion of the diaphragm was upstaged (from T3 to T4), while invasion of the mediastinal pleura was deleted as a descriptor. Figure 1 shows the survival curves according to clinical (cT) and pathologic (pT) T descriptors. Visceral pleural invasion, defined as the involvement of its elastic layer, was well assigned to its T2 category, but specific analyses of this descriptor showed that the 2 types of invasion (PL1, tumor invades beyond the elastic layer; and PL2, tumor invades to the pleural surface) had different prognoses, PL2 being associated with the worst outcome. Figure 2 shows a graphic representation of the different types of visceral pleural involvement and their definitions. The finding that visceral pleural invasion is not only a negative prognostic factor but that separation of PL1 and PL2 further stratifies prognostic subgroups indicates that its precise assessment for depth of invasion should be actively pursued. Elastic stains are recommended to clarify the status of visceral pleural invasion for cases in which initial hematoxylin-and-eosin–stained slides show that the tumor abuts the pleura and there is any question whether invasion is present.

**The N Descriptors**

Analyses of the current N descriptors at clinical and pathological staging showed that they clearly separate tumors of significantly different prognosis (Fig. 3). Therefore, there was no need to suggest any modifications. On this occasion, quantification of nodal disease was also explored. For the seventh edition, quantification was based on the number of the newly defined nodal zones. The nodal zones group neighboring nodal stations. For example, the upper mediastinal nodal stations, including the right and left superior and inferior paratracheal, prevascular, and retrotracheal nodal stations are grouped in the upper zone; and the lobar, segmental, and subsegmental nodal stations are
grouped in the peripheral zone (Table 2) (Fig. 4). It was found that the number of involved nodal zones had prognostic impact. For the eighth edition, the number of involved nodal stations was considered. The nodal stations contain lymph nodes that are located within clearly defined anatomic landmarks in the lung, the hilum, the mediastinum, and the supraclavicular area (Table 2). Similar to the nodal zones, the more involved nodal stations, the worse the prognosis. These findings derived exclusively from pathologic staging after examination of the resected lymphadenectomy specimens and could not be reproduced at clinical staging. This is the main reason why they were not used to modify the N descriptors. However, both the number of involved nodal zones and the number of involved nodal stations allow the refinement of postoperative prognosis and assist in making decisions on adjuvant therapy. The recommendation is to define nodal involvement in a quantitative way, especially at pathological staging, but also at clinical staging with the available means. Clinical quantification of nodal disease—based on anatomic and metabolic images; on transbronchial needle aspirations, either blind or assisted by ultrasound (endobronchial ultrasound transbronchial needle aspiration); on transesophageal fine-needle aspirations assisted by ultrasound; or on limited biopsies at surgical staging with mediastinoscopy or thoracoscopy—in general will be less accurate that pathologic quantification based on the study of the lymphadenectomy specimen.

Nodal quantification by the number of involved nodal stations is defined as follows:

- N1a: involvement of a single N1 nodal station;
- N1b: involvement of multiple N1 nodal stations;
- N2a1: involvement of a single N2 nodal station without N1 involvement (skip metastasis);
- N2a2: involvement of a single N2 nodal station with N1 involvement; and
- N2b: involvement of multiple N2 nodal stations.

Prognosis worsens as the number of involved nodal stations increases, but N1b and N2a1 have the same prognosis. This new analysis shows that discreet (one-station) mediastinal nodal disease without N1 disease has the same prognosis as multiple N1 stations. Five-year survival rates in the population of patients who underwent complete resection for the different N subcategories are: N1a, 59%; N1b, 50%; N2a1, 54%; N2a2, 43%; and N2b, 38%.

Figure 4 shows the lymph node map with specification of nodal stations and zones, and Table 2 defines the anatomic limits of the nodal stations and their grouping into nodal zones.
### TABLE 2. Anatomic Limits of the Nodal Stations of the International Association for the Study of Lung Cancer Lymph Node Map and Their Grouping in Nodal Zones

| LYMPH NODE STATION NO. | ANATOMICAL LIMITS |
|------------------------|-------------------|
| **Supraclavicular zone** |                   |
| 1: Low cervical, supraclavicular, and sternal notch nodes | • Upper border: Lower margin of cricoid cartilage  
• Lower border: Clavicles bilaterally and, in the midline, the upper border of the manubrium; 1R designates right-sided nodes, and 1L designates left-sided nodes in this region  
• For lymph node station 1, the midline of the trachea serves as the border between 1R and 1L |
| **Upper zone** |                   |
| 2: Upper paratracheal nodes | • 2R: Upper border: Apex of the right lung and pleural space and, in the midline, the upper border of the manubrium  
• Lower border: Intersection of caudal margin of innominate vein with the trachea  
• Similar to lymph node station 4R, 2R includes nodes extending to the left lateral border of the trachea  
• 2L: Upper border: Apex of the lung and pleural space and, in the midline, the upper border of the manubrium  
• Lower border: Superior border of the aortic arch |
| 3: Prevascular and retrotracheal nodes | • 3a: Prevascular  
• On the right: Upper border, apex of chest; lower border, level of carina; anterior border, posterior aspect of sternum; posterior border, anterior border of superior vena cava  
• On the left: Upper border, apex of chest; lower border, level of carina; anterior border, posterior aspect of sternum; posterior border, left carotid artery  
• 3p: Retrotracheal  
• Upper border, apex of chest; lower border, carina |
| 4: Lower paratracheal nodes | • 4R: Includes right paratracheal nodes and pretracheal nodes extending to the left lateral border of the trachea  
• Upper border: Intersection of caudal margin of innominate vein with the trachea  
• Lower border: Lower border of the azygos vein  
• 4L: Includes nodes to the left of the left lateral border of the trachea, medial to the ligamentum arteriosum  
• Upper border: Upper margin of the aortic arch  
• Lower border: Upper rim of the left main pulmonary artery |
| **Aortopulmonary zone** |                   |
| 5: Subaortic (aortopulmonary window) | • Subaortic lymph nodes lateral to the ligamentum arteriosum  
• Upper border: The lower border of the aortic arch  
• Lower border: Upper rim of the left main pulmonary artery |
| 6: Para-aortic nodes (ascending aorta or phrenic) | • Lymph nodes anterior and lateral to the ascending aorta and aortic arch  
• Upper border: A line tangential to the upper border of the aortic arch  
• Lower border: The lower border of the aortic arch |
| **Subcarinal zone** |                   |
| 7: Subcarinal nodes | • Upper border: The carina of the trachea  
• Lower border: The upper border of the lower lobe bronchus on the left; the lower border of the bronchus intermedius on the right |
The M Descriptors

The information from patients registered through the EDC system enabled specific analyses of the number and location of extrathoracic metastases and validation of the current M1a descriptors. Figure 5A shows the survival curves for the M1a descriptors. All have similar prognosis. These results validated the M1a descriptors proposed in the seventh edition; therefore, no modifications are needed.\(^{10}\)

Specific analyses of the sites of metastases showed that most had similar prognosis, but adrenal metastases tended to have worse prognosis. However, when the number of metastases was studied, patients with a single metastasis had significantly better prognosis than those with several metastases either in one organ or in several organs. Therefore, there was reliable enough data to recategorize M1b as those tumors with a single extrathoracic metastasis and to create the new category M1c for those tumors with multiple extrathoracic metastases in one organ or several organs. Figure 5B shows the survival curves of patients with endothermic metastasis (M1a), with a single extrathoracic metastasis (M1b) and with multiple extrathoracic metastases (M1c).\(^{10}\) M1a and M1b tumors have similar prognosis, but it makes sense to keep them separate, because they represent different forms of metastatic involvement and require different diagnostic and therapeutic approaches.

The Stages

There are modifications in the stage grouping. Some stages accommodate tumors with TNMs that belonged to other stages in the previous edition of the classification, and others were created to separate groups of tumors with significantly different prognosis. Stage IA is now divided into stages IA1, IA2, and IA3 to include the new T1a, T1b, and T1c N0M0 tumors. Stages IB and IIA now group T2aN0M0 and T2bN0M0 tumors, respectively. All N1M0 tumors are now grouped into stage IIB, together with T3N0M0, except for T3-T4N1M0 tumors, which are grouped into stage IIIA. Similarly, all N2M0 tumors

---

Reprinted and adapted from: Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC Lung Cancer Staging Project. A proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4 568-5778 with permission from Elsevier.
FIGURE 4. International Association for the Study of Lung Cancer (IASLC) Lymph Node Map. AP indicates aortopulmonary; Ao, aorta; Eso, esophagus; L, left; MPA, main pulmonary artery; R, right; SCV, superior vena cava; T, trachea. Copyright © 2009 Aletta Ann Frazier, MD. Reprinted from: Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC Lung Cancer Staging Project. A proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568-577 with permission from Elsevier.
are now stage IIIA, except for T3-T4N2M0 tumors, which are in stage IIIB, together with all N3M0 tumors, except for T3-T4N3M0 tumors, for which a new stage IIIC was created. Finally, stage IV is now divided into stage IVA to group M1a and M1b tumors and stage IVB to include M1c tumors. Figure 6 shows the survival graphs and survival rates of the clinical and pathologic stages from the eighth edition. There is the expected worsening in survival as tumor stage increases. All survival differences are significant except for those between stages IIIC and IVA. Despite the lack of survival differences, it makes sense to have these tumors in different stages, as they represent different forms of disease extent (locoregional and metastatic, respectively).

Table 3 shows the definitions of the T, N, and M descriptors for the eighth edition of the TNM classification for lung cancer.
**TABLE 3. Categories, Subcategories, and Descriptors of the Eighth Edition of the TNM Classification of Lung Cancer**

| CATEGORY | SUBCATEGORY | DESCRIPTORS |
|----------|-------------|-------------|
| T: Primary tumor | TX | Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy |
| | T0 | No evidence of primary tumor |
| | Tis | Carcinoma in situ:  
| | |  
| | |  
| | |  
| | | Tis (AIS): adenocarcinoma  
| | | Tis (SCIS): squamous cell carcinoma |
| | T1 | Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (ie, not in the main bronchus); the uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a  
| | T1mi | Minimally invasive adenocarcinoma  
| | T1a | Tumor 1 cm or less in greatest dimension  
| | T1b | Tumor more than 1 cm but not more than 2 cm in greatest dimension  
| | T1c | Tumor more than 2 cm but not more than 3 cm in greatest dimension |
| | T2 | Tumor more than 3 cm but not more than 5 cm; or tumor with any of the following features (T2 tumors with these features are classified T2a if 4 cm or less or if size cannot be determined and as T2b if greater than 4 cm but not larger than 5 cm):  
| | | Involves main bronchus regardless of distance to the carina, but without involving the carina  
| | | Involves visceral pleura  
| | | Associated with atelectasis or obstructive pneumonitis that extends to the hilar region, either involving part of the lung or the entire lung  
| | T2a | Tumor more than 3 cm but not more than 4 cm in greatest dimension  
| | T2b | Tumor more than 4 cm but not more than 5 cm in greatest dimension |
| | T3 | Tumor more than 5 cm but not more than 7 cm in greatest dimension or one that directly invades any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or associated separate tumor nodule(s) in the same lobe as the primary  
| | T4 | Tumors more than 7 cm or one that invades any of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina; separate tumor nodule(s) in a different ipsilateral lobe to that of the primary |
| N: Regional lymph nodes | NX | Regional lymph nodes cannot be assessed |
| | N0 | No regional lymph node metastasis |
| | N1 | Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension |
| | N2 | Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) |
| | N3 | Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral, or contralateral scalene, or supraclavicular lymph node(s) |
| M: Distant metastasis | MO | No distant metastasis |
| | M1 | Distant metastasis  
| | M1a | Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural or pericardial effusion; most pleural (pericardial) effusions with lung cancer are due to tumor; in a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and is not an exudate; where these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor |
| | M1b | Single extrathoracic metastasis in a single organ and involvement of a single distant (nonregional) node |
| | M1c | Multiple extrathoracic metastases in one or several organs |

Reprinted and adapted from: Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the stage grouping in the forthcoming (8th) edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11:39-5111 with permission from Elsevier.
This classification applies to small cell and nonsmall cell lung cancers and to bronchopulmonary carcinoids, but it does not apply to sarcomas or other rare tumors of the lung.

Uniform Classification of Situations Not Covered in the T, N, and M Descriptors

Despite the periodic revisions of the TNM classification, there are situations that remain uncovered by the different descriptors. Over the years, these situations have been debated, and recommendations on how to classify them have been reached by consensus. The following recommendations are provided to facilitate homogenous classification:

- Paralysis of the recurrent laryngeal nerve, superior vena cava obstruction, and compression of the trachea or esophagus related to direct extension of the primary tumor are classified as T4 but would be classified as N2 if caused by ipsilateral mediastinal nodal disease.
- Pancoast (superior sulcus) tumors are classified as T4 if there is evidence of invasion of the vertebral body or spinal canal, encasement of the subclavian vessels, or unequivocal involvement of the superior branches of the brachial plexus (C8 or above) but as T3 if these situations are not present.
- Direct invasion of an adjacent lobe, across the fissure or directly if the fissure is incomplete, is classified as T2a, unless other criteria assign a higher T category.
- Invasion of the phrenic nerve is T3, but invasion of the recurrent laryngeal nerve is T4.
- Invasion into hilar fat is classified as T2a, unless other criteria assign a higher T category.
- Direct extension to visceral pericardium and invasion into the mediastinal fat are classified as T4.
- Involvement of great vessels, ie, aorta, superior vena cava, inferior vena cava, main pulmonary artery (pulmonary trunk), intrapericardial portions of the right and left pulmonary artery, and intrapericardial portions of the superior and inferior right and left pulmonary veins, is classified as T4.
- Discontinuous tumor nodules in the ipsilateral parietal or visceral pleura are classified as M1a; but, if the tumor nodules are outside the parietal pleura in the chest wall or in the diaphragm, they are classified as M1b, if single, or M1c, if multiple.

New Site-Specific Recommendations

The analyses of the IASLC database, the review of published articles, and a series of international and multidisciplinary consensus meetings generated the following new lung cancer-specific recommendations, which are implemented in the eighth edition of the TNM classification of lung cancer.

Introduction of Tis (Adenocarcinoma in Situ) and T1mi

Since publication of the seventh edition of the TNM classification, new entities of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. Previously, Tis referred only to squamous cell carcinoma in situ; but now, criteria for the diagnosis of AIS and for its clinical staging by computed tomography (CT) and pathologic staging are defined. It also is recommended to designate the histologic type of

---

**TABLE 4. Stage Grouping of the Eighth Edition of the TNM Classification of Lung Cancer**

| STAGE | T     | N     | M     |
|-------|-------|-------|-------|
| Occult carcinoma | TX    | N0    | M0    |
| 0     | Tis   | N0    | M0    |
| IA1   | T1mi  | N0    | M0    |
| IA2   | T1b   | N0    | M0    |
| IA3   | T1c   | N0    | M0    |
| IB    | T2a   | N0    | M0    |
| IA    | T2b   | N0    | M0    |
| II    | T1a,b,c | N1 | M0    |
| IIIB  | T1a,b,c | N2 | M0    |
| IIIA  | T2a,b | N2    | M0    |
| III   | T3    | N0    | M0    |
| IVA   | Any T | Any N | M1a   |
| IVB   | Any T | Any N | M1b   |

Abbreviations: T1mi, minimally invasive adenocarcinoma; Tis, tumor in situ. Reprinted and adapted from: Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the stage grouping in the forthcoming (8th) edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11:39-51 with permission from Elsevier.
carcinoma in situ: Tis (AIS) for AIS and Tis (SCIS) for squamous cell carcinoma in situ. In addition, it is recommended to use T1mi for lesions suspected to be MIA by CT or confirmed pathologically as MIA. Figure 7 shows how to classify small adenocarcinomas at both clinical and pathologic staging and provides definitions for each category.

**Measurement of Tumor Size in Part-Solid Nonmucinous Adenocarcinomas**

Part-solid adenocarcinomas present with both solid and ground-glass components on CT. At pathological examination, the solid component usually corresponds to the invasive part, and the ground-glass component corresponds to the lepidic part (with growth restricted to the lepidic patterns observed microscopically and between solid components observed on CT and histologically identified invasive patterns. A pathologic differential diagnosis is listed for each of the proposed possibilities on CT imaging. Final pathologic T (pT) categories of these tumors require complete pathologic examination in resected specimens. Tis (adenocarcinoma in situ [AIS]): (cT) These lesions typically show a pure GG nodule (GGN) measuring ≤3 cm. However, pure GGN can also be minimally invasive adenocarcinoma (MIA) or invasive adenocarcinoma (AD) (double daggers). (pT) MIA histologically shows a lepidic-predominant adenocarcinoma nodule measuring ≤3 cm (double daggers). If the pure GGN or lepidic-predominant nodule measures >3.0 cm, then it is classified as lepidic-predominant adenocarcinoma (LPA) and should be staged as T1a. T1mi: (cT) MIA usually has a GG-predominant nodule ≤3 cm with a solid component that should appear ≤0.5 cm (single and double daggers). Although some MIsAs have a larger solid component on CT because of other benign components, such as scar or organizing pneumonia, these cases can only be diagnosed by pathologic examination. (pT) MIA histologically shows a lepidic-predominant adenocarcinoma nodule measuring ≤3 cm with an invasive component measuring ≤0.5 cm (single and double daggers). T1a: (cT) These have GG-predominant nodules measuring ≤3.0 cm with a solid component measuring 0.6 to 1.0 cm (single dagger). (pT) When an LPA measuring ≤3.0 cm has an invasive component measuring 0.6 to 1.0 cm, it is classified as pT1a (single dagger). T1b: (cT) These have GG-predominant nodules measuring ≤3.0 cm with a solid component measuring 1.1 to 2.0 cm (single dagger). (pT) When an LPA measuring ≤3.0 cm has an invasive component measuring 1.1 to 2.0 cm, it is classified as pT1b (single dagger). T1c: (cT) GG-predominant nodules measuring ≤3.0 cm with a solid component measuring 2.1 to 3.0 cm are classified as T1c (single dagger). When an invasive adenocarcinoma with a lepidic component measuring ≤3.0 cm has an invasive component measuring 2.1 to 3.0 cm, it is classified as T1c (single dagger). An asterisk indicates that all of the cT categories are presumptive, assuming that the GG versus solid components correspond to lepidic versus invasive components, respectively, on pathologic examination of a resected specimen. For the cT category, rule number 4 of the TNM classification is applied (when in doubt, opt for the lesser category; single dagger). In cases where there are multiple foci of solid or invasive components, the suggested way to estimate the invasive size is to sum the percentage area of the invasive components and multiply this amount by the overall tumor diameter (double daggers). Size is the only distinguishing feature between atypical adenomatous hyperplasia (AAH) and AIS (double daggers). If a pure GGN identified by CT or pure lepidic adenocarcinoma identified by pathology is larger than 3 cm, then it should be staged as cT1a or pT1a, respectively (double daggers). If the total tumor size is larger than 3.0 cm, then, depending on the invasive size, these categories can be classified as T1a, T1b, or T1c. As shown in Table 4, Tis (AIS) is stage 0, and T1mi is stage IA1. Reprinted from: Travis WD, Asamura H, Bankier A, et al. The IASLC Lung Cancer Staging Project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11:1204-1223 with permission from Elsevier.

---

**FIGURE 7.** Proposed Eighth Edition Clinical and Pathologic T Descriptor Classification of Small (≤3 cm) Lung Adenocarcinomas With Ground-Glass and Lepidic Components by Computed Tomography and Pathology. Clinical T (cT) categories: Computed tomography (CT) images on high-resolution CT (HRCT) can be suggestive of pathologic diagnoses, but they are not specific, because ground-glass (GG) opacities do not always correspond to lepidic patterns, and solid components do not always correlate with invasive components. However, there is a general correlation between GG observed on CT and lepidic patterns observed microscopically and between solid components observed on CT and histologically identified invasive patterns. A pathologic differential diagnosis is listed for each of the proposed possibilities on CT imaging. Final pathologic T (pT) categories of these tumors require complete pathologic examination in resected specimens. Tis (adenocarcinoma in situ [AIS]): (cT) These lesions typically show a pure GG nodule (GGN) measuring ≤3 cm. However, pure GGN can also be minimally invasive adenocarcinoma (MIA) or invasive adenocarcinoma (AD) (double daggers). (pT) MIA histologically shows a lepidic-predominant adenocarcinoma nodule measuring ≤3 cm (double daggers). If the pure GGN or lepidic-predominant nodule measures >3.0 cm, then it is classified as lepidic-predominant adenocarcinoma (LPA) and should be staged as T1a. T1mi: (cT) MIA usually has a GG-predominant nodule ≤3 cm with a solid component that should appear ≤0.5 cm (single and double daggers). Although some MIsAs have a larger solid component on CT because of other benign components, such as scar or organizing pneumonia, these cases can only be diagnosed by pathologic examination. (pT) MIA histologically shows a lepidic-predominant adenocarcinoma nodule measuring ≤3 cm with an invasive component measuring ≤0.5 cm (single and double daggers). T1a: (cT) These have GG-predominant nodules measuring ≤3.0 cm with a solid component measuring 0.6 to 1.0 cm (single dagger). (pT) When an LPA measuring ≤3.0 cm has an invasive component measuring 0.6 to 1.0 cm, it is classified as pT1a (single dagger). T1b: (cT) These have GG-predominant nodules measuring ≤3.0 cm with a solid component measuring 1.1 to 2.0 cm (single dagger). (pT) When an LPA measuring ≤3.0 cm has an invasive component measuring 1.1 to 2.0 cm, it is classified as pT1b (single dagger). T1c: (cT) GG-predominant nodules measuring ≤3.0 cm with a solid component measuring 2.1 to 3.0 cm are classified as T1c (single dagger). When an invasive adenocarcinoma with a lepidic component measuring ≤3.0 cm has an invasive component measuring 2.1 to 3.0 cm, it is classified as T1c (single dagger). An asterisk indicates that all of the cT categories are presumptive, assuming that the GG versus solid components correspond to lepidic versus invasive components, respectively, on pathologic examination of a resected specimen. For the cT category, rule number 4 of the TNM classification is applied (when in doubt, opt for the lesser category; single dagger). In cases where there are multiple foci of solid or invasive components, the suggested way to estimate the invasive size is to sum the percentage area of the invasive components and multiply this amount by the overall tumor diameter (double daggers). Size is the only distinguishing feature between atypical adenomatous hyperplasia (AAH) and AIS (double daggers). If a pure GGN identified by CT or pure lepidic adenocarcinoma identified by pathology is larger than 3 cm, then it should be staged as cT1a or pT1a, respectively (double daggers). If the total tumor size is larger than 3.0 cm, then, depending on the invasive size, these categories can be classified as T1a, T1b, or T1c. As shown in Table 4, Tis (AIS) is stage 0, and T1mi is stage IA1. Reprinted from: Travis WD, Asamura H, Bankier A, et al. The IASLC Lung Cancer Staging Project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11:1204-1223 with permission from Elsevier.
neoplastic cells along preexisting alveolar structures and lacking stromal, vascular, alveolar space, or pleural invasion). To define the T category by tumor size, only the size of the solid component on CT or the size of the invasive component at pathologic examination are considered, because it is the size of the solid/invasive component that determines prognosis. However, documentation of both the size of the solid component/invasive part and of the whole tumor, including the ground-glass and lepidic components in radiology and pathology reports, respectively, is recommended.\(^{18}\)

**Measurement of Tumor Size After Induction (Preoperative) Therapy**

In cases where a single, discrete, measurable focus of viable tumor is not identifiable, it can be difficult to estimate tumor size after induction (preoperative) therapy. In such cases, the recommendation of the IASLC to determine tumor size at pathologic staging after induction (preoperative) therapy (ypT) is that tumor size can be measured by multiplying the percentage of viable tumor cells by the total size of the tumor.\(^{18}\)

**Classification of Lung Cancers With Multiple Sites of Involvement**

To avoid ambiguity and to facilitate the homogeneous classification of lung cancer with multiple sites of disease, an ad hoc subcommittee of the IASLC Staging and Prognostic Factors Committee developed the following recommendations based on analyses of the IASLC database for which data were available, the review of published reports, and a wide multidisciplinary and international consensus. The following recommendations apply not only to grossly identified tumors but also to those identified at microscopic examination, and they differ depending on the pattern of disease.\(^{19}\)

**Synchronous and metachronous primary lung cancers**

Regardless of tumor location, a separate TNM is defined for each primary tumor. The clinical and pathological criteria to differentiate second primary tumors from related tumors are defined in Table 5.\(^{20}\)

**Separate tumor nodules with similar histopathologic features (intrapulmonary metastases)**

Classification depends on the location of the separate tumor nodule(s): T3 if the separate tumor nodule(s) is(are) in the same lobe as the primary tumor, T4 if located in a different ipsilateral lobe, and M1a if located in the contralateral lung. If there are additional extrathoracic metastases, then the tumor will be classified as M1b or M1c, depending on the number of metastatic sites. The clinical and pathological criteria to categorize separate tumor nodules (intrathoracic metastasis) are defined in Table 6.\(^{21}\)

**Multifocal pulmonary adenocarcinoma with ground-glass/lepidic features**

Regardless of the location of the tumors, the rule of the highest T with the number (#) or (m) (for multiple in parentheses) and an N and an M for all of the multiple tumors collectively applies for these tumors. For example, a patient has a part-solid tumor of 3 cm in greatest dimension consisting of a predominant ground-glass opacity and a 4-mm solid component in the right upper lobe; in addition, there are 3 pure ground-glass opacities in the right lung and 2 pure ground-glass opacities in the left lung measuring between 1 and 3 cm; and there is no suspicion of nodal involvement on CT. The clinical classification of this tumor would be: cT1mi(6) N0 M0. In the absence of a pathologic diagnosis, this classification shows that the most advanced tumor is likely to be a minimally invasive adenocarcinoma (the ground-glass component corresponding to the lepidic part and the solid component corresponding to the invasive part, being minimally invasive because it measures less than 5 mm) accompanied by 5 other lesions that are less invasive, that is, they have a lower T classification. If T1mi is the most advanced, then the other 5 lesions can only be adenocarcinomas in situ: Tis (AIS). Table 7 shows the clinical and pathologic criteria for defining these tumors.\(^{22}\)

**Diffuse pneumonic-type lung adenocarcinoma**

If the disease presents with a single focus, then the general TNM classification is applied, with the T category defined by tumor size. When multiple foci of disease are present, tumor classification is based on the location of the involved areas (including miliary involvement; ie, multiple small nodules in the lung parenchyma): T3 if located in one lobe, T4 if located in other ipsilateral lobes, and M1a if the contralateral lung is involved, with the T category defined by the largest tumor. When it is difficult to determine tumor size, T4 applies if there is evidence of involvement of another ipsilateral lobe. In all circumstances, the N category should apply to all pulmonary sites, and the appropriate M category should be applied, depending on the number and location of metastases. The clinical and pathological criteria to define these tumors are shown in Table 8.\(^{22}\)

Table 9 summarizes the basic radiographic and pathological features, the recommended TNM classification, and the conceptual view of the 4 patterns of lung cancer with multiple sites of involvement.\(^{19}\)

**Implications for Clinical Practice and Research**

All new editions of the TNM classification bring changes in clinical practice and prospects for further research. The specific implications for clinical practice and research brought by the eighth edition are summarized as follows:
Concerning the T Component

- Tumor size must be accurately measured, because small changes in size mean considerable differences in survival.
- Both physicians and patients must be aware of the prognostic relevance of tumor size when a decision to follow up lung nodules without pathologic diagnosis is made.
- Accurate tumor size measurement is also relevant in part-solid tumors; this implies measurement of the solid component on CT and of the invasive part on microscopic examination.

- Refinement of methods to measure tumor size with radiologic and pathologic correlation is a topic that needs further research.
- Visceral pleural invasion has been confirmed as an important prognostic factor and should be actively looked for by the pathologist; elastic stains should be used if visceral pleural invasion is not evident on hematoxylin-and-eosin staining.
- The smallest coded tumors, ≤1 cm in size (T1a), and Tis (AIS) and T1mi may constitute research opportunities to investigate tumor growth rate,

---

### TABLE 5. Criteria for Separate Versus Related Pulmonary Tumors

| Clinical criteria<sup>a</sup> |
|-------------------------------|
| Tumors may be considered separate primary tumors if: |
| They are clearly of a different histologic type (eg, squamous carcinoma and adenocarcinoma) by biopsy |
| Tumors may be considered to be arising from a single tumor source if: |
| Exactly matching breakpoints are identified by comparative genomic hybridization |
| Relative arguments that favor separate tumors: |
| Different radiographic appearance or metabolic uptake |
| Different biomarker pattern (driver gene mutations) |
| Different rates of growth (if previous imaging is available) |
| Absence of nodal or systemic metastases |
| Relative arguments that favor a single tumor source: |
| Same radiographic appearance |
| Similar growth patterns (if previous imaging is available) |
| Significant nodal or systemic metastases |
| Same biomarker pattern (and same histotype) |

| Pathologic criteria (ie, after resection)<sup>b</sup> |
|-------------------------------|
| Tumors may be considered separate primary tumors if: |
| They are clearly of a different histologic type (eg, squamous carcinoma and adenocarcinoma) |
| They are clearly different by a comprehensive histologic assessment |
| They are squamous carcinomas that have arisen from carcinoma in situ |
| Tumors may be considered to be arising from a single tumor source if: |
| Exactly matching breakpoints are identified by comparative genomic hybridization |
| Relative arguments that favor separate tumors (to be considered together with clinical factors): |
| Different pattern of biomarkers |
| Absence of nodal or systemic metastases |
| Relative arguments that favor a single tumor source (to be considered together with clinical factors): |
| Matching appearance on comprehensive histologic assessment |
| Same biomarker pattern |
| Significant nodal or systemic metastases |

<sup>a</sup>Note that a comprehensive histologic assessment is not included in clinical staging, as it requires that the entire specimen has been resected.

<sup>b</sup>Pathologic information should be supplemented with any clinical information that is available. Reprinted from: Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:651-665 with permission from Elsevier.
tumor density on CT and magnetic resonance imaging, intensity of standardized uptake values of positron emission tomography, types of resection (lobectomy vs segmentectomy and wedge resection), alternative nonsurgical therapies, molecular profiles, and genetic signatures.

- The diversity of tumor sizes found in all T categories may help stratify future clinical trials.

Concerning the N Component
- Quantification of nodal disease has prognostic relevance, and it should be determined according to the

### TABLE 6. Criteria to Categorize a Lesion as a Separate Tumor Nodule (Intrapulmonary Metastasis)\(^a\)

| Clinical criteria                                                                 | Pathologic criteria                                                                 |
|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Tumors should be considered to have a separate tumor nodule(s) if:                | Tumors should be considered to have a separate tumor nodule(s) (intrapulmonary metastasis) if: |
| There is a solid lung cancer and a separate tumor nodule(s) with a similar solid appearance and with (presumed) matching histologic appearance | | |
| • This applies whether or not a biopsy has been performed on the lesions, provided that there is strong suspicion that the lesions are histologically identical | AND provided that: |
| • This applies whether or not there are sites of extrathoracic metastases          | The lesions are NOT judged to be synchronous primary lung cancers                 |
| AND provided that:                                                               | The lesions are NOT multifocal GG/L lung cancer (multiple nodules with ground-glass/lepidic features) or a pneumonic type of lung cancer |

**Abbreviations:** AIS, adenocarcinoma in situ; GG/L, ground glass/lepidic; LPA, lepidic-predominant adenocarcinoma; MIA, minimally invasive adenocarcinoma.

*Note: A radiographically solid appearance and the specific histologic subtype of solid adenocarcinoma denote different things. Reprinted from: Detterbeck FC, Bolejack V, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: background data and proposals for the classification of lung cancer with separate tumor nodules in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:681-69221 with permission from Elsevier.

### TABLE 7. Criteria Identifying Multifocal Ground-Glass/Lepidic Lung Adenocarcinoma\(^a\)

| Clinical criteria                                                                 | Pathologic criteria                                                                 |
|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Tumors should be considered multifocal GG/L lung adenocarcinoma if:               | Tumors should be considered multifocal GG/L lung adenocarcinoma if:                 |
| There are multiple subsolid nodules (either pure ground glass or part-solid), with at least one suspected (or proven) to be cancer | There are multiple foci of LPA, MIA, or AIS |
| • This applies whether or not a biopsy has been performed of the nodules          | • This applies whether a detailed histologic assessment (ie, proportion of subtypes, etc) shows a matching or different appearance |
| • This applies if the other nodules(s) are found on biopsy to be AIS, MIA, or LPA  | • This applies if one lesion(s) is LPA, MIA, or AIS and there are other subsolid nodules |
| • This applies if a nodule has become >50% solid but is judged to have arisen from a GGN, provided there are other subsolid nodules | • This applies whether the nodule(s) is (are) identified preoperatively or only on pathologic examination |
| • GGN lesions <5 mm or lesions suspected to be AAH are not counted                | • Foci of AAH are not counted                                                      |

**Abbreviations:** AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; GGN, ground-glass nodule; LPA, lepidic predominant adenocarcinoma; MIA, minimally invasive adenocarcinoma.

*Note: A radiographically solid appearance and the specific histologic subtype of solid adenocarcinoma denote different things. Reprinted from: Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic-type of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol. 2016;11:666-68022 with permission from Elsevier.
number of involved nodal stations or the number of
involved nodal zones, especially at pathological staging,
to refine prognosis and make decisions on adjuvant
therapy, but also at clinical staging, when the initial
therapeutic decisions are made.
• Upfront surgery for single-station N2 disease without
N1 disease will be discussed by surgeons, but its propo-
sants will have to be aware that the results on quantifi-
cation of nodal disease derive from pathologic staging
and could not be reproduced at clinical staging, when
therapeutic decisions are made. Therefore, this surgical
approach can only be applied if a very thorough medi-
astinoscopy is performed at the time of clinical staging
with the objective not only to biopsy lymph nodes but
also to perform a lymphadenectomy of the upper medi-
astinum (transcervical mediastinoscopic lymphadenec-
tomy). It is important to realize that even the smallest
solid tumors can be associated to mediastinal nodal dis-
ease. In the IASLC database used to inform the eighth
edition of the TNM classification, pN3 was found in
less than 1% of the 3 pT1 subcategories. However, the
rate of pN2 disease was 3.21% for pT1a, 6.27% for
T1b, and 9.44% in T1c. The rates of pN1 disease were
3.08% for pT1a, 4.92% for pT1b, and 8.98% for pT1c.
These results are important when making decisions on
the use of imaging, metabolic, and invasive methods at
clinical staging.
• The IASLC lymph node map (Fig. 4) should be used
to classify nodal disease; otherwise, international data
will never be homogeneous.

Concerning the M Component
• It is important to register the number of metastases
and their location.
• The separate classification of a single extrathoracic
metastasis (M1b) from multiple extrathoracic meta-
stases (M1c) will help to clarify the future definitions of
oligometastasis and oligoprogression and to facilitate
the research on radical treatment of patients with these
conditions.

Concerning the Stage Grouping:
• Although therapeutic protocols are based on tumor
stage and histologic type, a taxonomic change in stage
per se does not suggest an automatic change in therapy;
therapeutic recommendations should derive from prop-
erly designed clinical trials and not from changes in
tumor classification.
• The creation of new stages in the eighth edition will help
the stratification of patients with lung cancer for future
clinical trials and the refinement in predicting prognosis.

Conclusion
The eighth edition of the TNM classification of lung can-
cer defines new tumor-size groups, confirms the prognostic
relevance of quantifying nodal disease, establishes a new
category for single extrathoracic metastasis, and creates new
stage groupings. In this way, it improves our understanding
of the anatomic extent of the tumor, enhances our capacity
to indicate prognosis at clinical and pathologic staging, and

---

TABLE 8. Criteria Identifying the Pneumonic Type of Adenocarcinoma\a

| Clinical criteria |
|------------------|
| Tumors should be considered a pneumonic type of adenocarcinoma if: |
| The cancer manifests in a regional distribution, similar to a pneumonic infiltrate or consolidation |
| • This applies whether there is one confluent area or multiple regions of disease; the region(s) may be confined to one lobe, in multiple lobes, or bilater-
  al, but should involve a regional pattern of distribution |
| • The involved areas may appear to be ground glass, solid consolidation, or a combination thereof |
| • This can be applied when there is compelling suspicion of malignancy whether or not a biopsy has been performed of the area(s) |
| • This should not be applied to discrete nodules (ie, GG/L nodules) |
| • This should not be applied to tumors causing bronchial obstruction with resultant obstructive pneumonia or atelectasis |

| Pathologic criteria |
|---------------------|
| Tumors should be considered pneumonic-type of adenocarcinoma if: |
| There is diffuse distribution of adenocarcinoma throughout a region(s) of the lung, as opposed to a single well demarcated mass or multiple, discrete well
demarcated nodules |
| • This typically involves an invasive mucinous adenocarcinoma, although a mixed mucinous and nonmucinous pattern may occur |
| • The tumor may show a heterogeneous mixture of acinar, papillary, and micropapillary growth patterns, although it is usually lepidic-predominant |

Abbreviation: GG/L, ground glass/lepidic. *Note: A radiographically solid appearance and the specific histologic subtype of solid adenocarcinoma denote differ-
ent things. Reprinted from: Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: background data and proposals for the
application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic-type of involvement in the
forthcoming eighth edition of the TNM classification. J Thorac Oncol. 2016;11:666-680 with permission from Elsevier.
TABLE 9. Schematic Summary of Patterns of Disease and TNM Classification in Patients Who Have Lung Cancer With Multiple Pulmonary Sites of Involvement

| VARIABLE | SECOND PRIMARY LUNG CANCER | SEPARATE TUMOR NODULE (INTRAPELICHIN MARATASIS) | MULTIFOCAL GG/L NODULES | PNEUMONIC TYPE OF ADENOCARCINOMA |
|----------|-----------------------------|-----------------------------------------------|------------------------|---------------------------------|
| Imaging features | Two or more distinct masses with imaging characteristics of lung cancer (eg, spiculated) | Typical lung cancer (eg, solid, spiculated) with separate solid nodule | Multiple ground-glass or part-solid nodules | Patchy areas of ground glass and consolidation |
| Pathologic features | Different histotype or different morphology by comprehensive histologic assessment | Distinct masses with the same morphologic features by comprehensive histologic assessment | Adenocarcinomas with prominent lepidic component (typically varying degrees of AIS, MIA, LPA) | Same histologic features throughout (most often invasive mucinous adenocarcinoma) |
| TNM classification | Separate cTNM and pTNM for each cancer | Location of separate nodule relative to primary site determines if T3, T4 or M1a; single N and M | T based on highest T lesion with (#/m) indicating multiplicity; single N and M | T based on size or T3 if in single lobe, T4 or M1a if in different ipsilateral or contralateral lobes; single N and M |
| Conceptual view | Unrelated tumors | Single tumor, with intrapulmonary metastasis | Separate tumors, albeit with similarities | Single tumor, diffuse pulmonary involvement |

Abbreviations: AIS, adenocarcinoma in situ; GG/L, ground glass/lepidic; LPA, lepidic-predominant adenocarcinoma; MIA, minimally invasive adenocarcinoma; p, pathologic; TNM, tumor, node, metastasis. *Reprinted from: Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC Lung Cancer Staging Project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol. 2016;11:539-650,* with permission from Elsevier.

Increases the possibilities of research by facilitating tumor stratification for future clinical trials.

Author Contributions: Ramón Rami-Porta: Conceptualization, methodology, validation, investigation, writing—original draft, writing—review and editing, visualization, and supervision. Hisao Asamura: Conceptualization, methodology, investigation, resources, writing—review and editing, and project administration. William D. Travis: Conceptualization, methodology, validation, investigation, writing—review and editing, visualization, and supervision. Valerie W. Rusch: Conceptualization, methodology, validation, formal analysis, investigation, resources, data curation, writing—original draft, writing—review and editing, visualization, supervision, and project administration.

References

1. Goldstraw P, Crowley JJ. The IASLC international staging project on lung cancer. J Thorac Oncol. 2006;1:281-286.
2. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706-714.
3. Rami-Porta R, Bolejack V, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2014;9:1618-1624.
4. Detterbeck FC, Chansky K, Groome P, et al. The IASLC Lung Cancer Staging Project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming (eighth) edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11:1433-1446.
5. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10:1675-1684.
6. Rami-Porta R, Bolejack V, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: proposals for the new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568-577.
7. Asamura H, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2:603-612.
8. Rami-Porta R, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classifications for lung cancer. J Thorac Oncol. 2015;10:1515-1522.
9. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39-51.
10. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the M descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10:1675-1684.
11. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the stage grouping in the forthcoming (8th) edition of the TNM classification of lung cancer. J Thorac Oncol. 2009;4:1049-1059.
12. Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:300-311.
19. Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC Lung Cancer Staging Project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. *J Thorac Oncol.* 2016;11:1204-1223.

20. Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer. *J Thorac Oncol.* 2016;11:539-650.

21. Detterbeck FC, Bolejack V, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: background data and proposals for the classification of lung cancer with separate tumor nodules in the forthcoming eighth edition of the TNM classification for lung cancer. *J Thorac Oncol.* 2016;11:651-665.

22. Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic-type of involvement in the forthcoming eighth edition of the TNM classification. *J Thorac Oncol.* 2016;11:681-692.